In addition, KDIGO has recently published its rst guideline related to Diabetes Management in CKD. High blood pressure (BP) is closely related to adverse kidney and cardiovascular outcomes in CKD. Thus, KDIGO published its rst guideline for the management of BP in CKD in 2012. The guideline was derived from a signi cant effort by the Work Group to summarize the evidence on this topic available through 2011. Since 2011, new evidence has emerged, which has important implications to be considered for future guideline updates. To this end, KDIGO convened a Controversies Conference to examine this new evidence as it relates to the management and treatment of high BP in CKD. The KDIGO Controversies Conference on Blood Pressure in CKD assembled a global panel of multidisciplinary clinical and scienti c experts to identify key issues relevant to the updating of the KDIGO 2012 Blood Pressure guideline. The objective of this conference was to assess the current state of knowledge related to the optimal means for measuring BP, management of high BP in CKD patients, with and without diabetes (including older adults), as well as the pediatric and kidney transplant subpopulations. A guideline update was recommended and commissioned following this Contro- versies Conference. In keeping with KDIGO s policy for transparency and rigorous public review during the guideline development process, the guideline scope was made available for open commenting prior to the start of the evidence review. The feedback received on the Scope of Work draft was carefully considered by the Work Group members. The guideline draft was also released for public review by external stakeholders. The Work Group has critically reviewed the feedback from the public input and revised the guideline as appropriate for the nal publication. We thank Alfred K. Cheung, MD and Johannes F.E. 